Loading...
XASX
NYR
Market cap56mUSD
Jul 10, Last price  
0.43AUD
1D
4.88%
1Q
-28.93%
IPO
91.11%
Name

Nyrada Inc

Chart & Performance

D1W1MN
XASX:NYR chart
P/E
—
P/S
35.83
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.83%
Rev. gr., 5y
16.32%
Revenues
2m
-26.07%
0486,3381,125,4142,336,0221,093,7441,429,9053,241,9242,396,734
Net income
-5m
L+249.56%
-2,416,276-4,094,804-5,773,667-3,526,180-3,973,364-7,816,295-1,386,227-4,845,671
CFO
-5m
L+559.27%
-690,181-2,005,199-4,410,623-2,762,606-2,933,806-7,231,404-766,295-5,051,947

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
URL
https://www.nyrada.com/site/content/
IPO date
Jan 16, 2020
Employees
Domiciled in
AU
Incorporated in
US

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT